Hercules Capital announced a $125 million debt‑facility expansion with enGene Holdings, providing $25 million already disbursed and up to $75 million in future tranches tied to clinical, regulatory, and commercial milestones, with a final tranche of up to $25 million subject to Hercules’ approval.
The facility strengthens enGene’s balance sheet ahead of a planned BLA filing for its lead gene‑therapy candidate, detalimogene voraplasmid, which targets high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ. The additional capital will support late‑stage development, regulatory submission, and potential commercialization while preserving equity for future growth.
For Hercules, the transaction aligns with its core strategy of providing structured debt with warrants to high‑growth life‑sciences companies. The $125 million commitment expands Hercules’ portfolio exposure to a promising gene‑therapy platform, offering potential warrant upside if the BLA is approved and the product is commercialized. Hercules, a business development company, has a track record of senior secured loans backed by intellectual property.
EnGene CEO Ron Cooper said the additional access to capital strengthens the balance sheet and provides financial flexibility for the BLA filing and potential 2027 launch. Hercules Senior Managing Director Bryan Jadot highlighted the partnership as a long‑term capital relationship and the company’s dedication to financing innovative life‑sciences companies through development and commercialization.
The deal underscores the growing need for specialized financing in the biotechnology sector, as companies advance novel therapies. Hercules’ involvement provides enGene with a non‑dilutive runway, while the potential warrant upside aligns Hercules’ interests with enGene’s future success.
Hercules reported Q3 2025 earnings per share of $0.49, slightly above analyst expectations, and revenue of $138.09 million, reflecting its disciplined underwriting and focus on high‑growth life‑sciences companies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.